Oculis Holding AG (OCS) 财报

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 60 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.